Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early
multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen
deprivation therapy(ADT) in men with biochemical recurrence (BCR) or who have a rising
Prostate Specific Antigen (PSA) after treatment of their prostate cancer with surgery or
radiation)
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc.